CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.

ABSTRACT:

Objective

To assess if the percentage of CD3(+)CD4(+)CD62L(+) cells in cryopreserved peripheral blood mononuclear cells (PBMCs) (here termed %CD62L) can predict risk of developing progressive multifocal leukoencephalopathy (PML) and better inform the physician for benefit-risk assessment of natalizumab treatment decisions in a global setting.

Methods

Cryopreserved PBMCs from 21 natalizumab-treated patients who developed PML and 104 matched natalizumab-treated patients with multiple sclerosis (MS) without PML collected as a part of Biogen clinical trials were retrospectively examined for CD3, CD4, CCR7, CD45RA, and CD62L by flow cytometry.

Results

In this cohort, %CD62L in natalizumab-treated patients did not predict PML risk. Natalizumab-treated patients with MS witho

SUBMITTER: Lieberman LA 

PROVIDER: S-EPMC4776091 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature